EM-T3Pharmacoepidemiology and Drug Safety2015-08-25第 24 卷第 11 期，1121-1132高影响力 · 前 10%
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach
